Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 40073 record(s)

Req # A-2023-001443

The cover letter which accompanied the Abbreviated New Drug Submission (ANDS) for Aripiprazole for which an ANDS was added to the Health Canada List of Generic Submissions Under Review (GSUR) on January 19, 2024. Screening Acceptance letter for the…

Organization: Health Canada

5 page(s)
August 2024

Req # A-2023-001460

The most recent Module 2.3: Quality Overall Summary (QOS) submitted the sponsor for the Third Desmopressin Abbreviated New Drug Submission (ANDS).

Organization: Health Canada

128 page(s)
August 2024

Req # A-2023-001462

The most recent Certified Product Information Document (CPID) submitted for the Third Desmopressin Abbreviated New Drug Submission (ANDS).

Organization: Health Canada

27 page(s)
August 2024

Req # A-2023-001485

The most recent Module 2.3: Quality Overall Summary (QOS) submitted the sponsor for the Degarelix Abbreviated New Drug Submission (ANDS).

Organization: Health Canada

157 page(s)
August 2024

Req # A-2023-001546

Medical Ingredient: "Ruxolitinib phosphate" Therapeutic Area: "Antineoplastic agents" Number of submissions under review: "1". The year and month in which the following submission was accepted for review; and the…

Organization: Health Canada

1 page(s)
August 2024

Req # A-2023-001555

All documents from October 1, 2022, to March 12, 2024, respecting the invitation, scheduling and appearance of Cameron MacDonald, Antonio Utano, Minh Doan and David Yeo before the House of Commons Standing Committee on Government Operations and…

Organization: Health Canada

112 page(s)
August 2024

Req # A-2023-001605

The Abbreviated New Drug Submission (ANDS) cover letter of the company who submitted the Semaglutide ANDS.

Organization: Health Canada

3 page(s)
August 2024

Req # A-2023-001608

Global Health Imports Corporation's medical device establishment licence, including the date it was issued and the date it was revoked.

Organization: Health Canada

16 page(s)
August 2024

Req # A-2023-001612

The name of the company who submitted the Semaglutide Abbreviated New Drug Submission (ANDS), and the year and month in which the Semaglutide ANDS was accepted for review.

Organization: Health Canada

1 page(s)
August 2024

Req # A-2024-000097

Pfizer was to submit a data/report package to Health Canada by December 1, 2023 with respect to SV40 Deoxyribonucleic acid (DNA) contamination in their covid vaccines. Pfizer described what they would provide to Health Canada as follows: "…

Organization: Health Canada

56 page(s)
August 2024
Date modified: